doi: 10.1161/01.CIR.0000164269.80908.9D
(Circulation. 2005;111:2391-2397.)
© 2005 American Heart Association, Inc.
Valvular Heart Disease |
B-Type Natriuretic Peptide in Organic Mitral Regurgitation
Determinants and Impact on Outcome
From the Division of Cardiovascular Diseases and Internal Medicine (D.D., D.M.-Z., J.-F.A., H.C., J.C.B., M.E.-S.) and the Section of Biostatistics (C.S.), Mayo Clinic, Rochester, Minn.
Correspondence to Maurice Enriquez-Sarano, MD, Mayo Clinic, 200 First St SW, Rochester, MN 55905. E-mail Sarano.maurice{at}mayo.edu
Received October 8, 2004; revision received December 20, 2004; accepted January 11, 2005.
Background— B-type natriuretic peptide (BNP) activation observed in cardiac diseases is a predictor of poor outcome; however, in organic mitral regurgitation (MR), BNP determinants and prognostic value are unknown.
Methods and Results— We prospectively enrolled 124 patients with chronic organic MR (aged 63±15 years, 60% males) in whom we measured BNP level and simultaneously quantified MR degree, left ventricular (LV) remodeling, and left atrial (LA) volumes and analyzed long-term outcome. Baseline BNP level (54±67 pg/mL, median 31 pg/mL) was associated univariately with multiple clinical and echocardiographic characteristics, but in multivariate analysis, independent determinants of BNP, beyond age and sex (both P
0.01), were LV end-systolic volume index, LA volume, atrial fibrillation, and symptoms (all P<0.02). Conversely, MR degree was not independently associated with BNP. During follow-up, patients with high versus low BNP (
31 versus <31 pg/mL) displayed lower survival rates (at 5 years, 72±10% versus 95±5%, P=0.03) and higher rates of the combined end point of death and heart failure (at 5 years, 42±10% versus 16±7%, P=0.03). In multivariate analysis, with adjustment for age, sex, functional class, MR severity, and ejection fraction, BNP was independently predictive of mortality (hazard ratio per 10 pg/mL, 1.23 [95% CI 1.07 to 1.48], P=0.004) and of death or heart failure (hazard ratio per 10 pg/mL, 1.09 [95% CI 1.001 to 1.19], P=0.04).
Conclusions— BNP activation in organic MR reflects primarily ventricular and atrial consequences rather than degree of MR. Higher BNP level in patients with organic MR independently predicts adverse events under conservative management. Therefore, BNP activation in organic MR is an emerging biomarker of severity of MR consequences and of poor clinical outcome, and its assessment should be considered in the clinical evaluation and risk stratification of patients with MR.
Key Words: natriuretic peptides • echocardiography • regurgitation • prognosis
This article has been cited by other articles:
 |
|
 |
|
  R. Pizarro, O. O. Bazzino, P. F. Oberti, M. Falconi, F. Achilli, A. Arias, J. G. Krauss, and A. M. Cagide Prospective validation of the prognostic usefulness of brain natriuretic peptide in asymptomatic patients with chronic severe mitral regurgitation. J. Am. Coll. Cardiol., September 15, 2009; 54(12): 1099 - 1106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Watanabe, M. Hirayama, A. Noda, M. Ito, N. Atsuta, J. Senda, T. Kaga, A. Yamada, M. Katsuno, T. Niwa, et al. B-type natriuretic peptide and cardiovalvulopathy in Parkinson disease with dopamine agonist Neurology, February 17, 2009; 72(7): 621 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vahanian, B. Iung, L. Piérard, R. Dion, and J. Pepper CHAPTER 21 Valvular Heart Disease ESC Textbook of Cardiovascular Medicine, January 1, 2009; 2(1): med-9780199566990-chapter - med-9780199566990-chapter. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Carlhall, T. C. Nguyen, A. Itoh, D. B. Ennis, W. Bothe, D. Liang, N. B. Ingels, and D. C. Miller Alterations in Transmural Myocardial Strain: An Early Marker of Left Ventricular Dysfunction in Mitral Regurgitation? Circulation, September 30, 2008; 118(14_suppl_1): S256 - S262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Kerr, O. C. Raffel, G. A. Whalley, I. Zeng, and R. A. Stewart Elevated B-type natriuretic peptide despite normal left ventricular function on rest and exercise stress echocardiography in mitral regurgitation Eur. Heart J., February 1, 2008; 29(3): 363 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Baumgartner Neurohormones in valvular heart disease: what can they tell us? Eur. Heart J., February 1, 2008; 29(3): 290 - 292. [Full Text] [PDF]
|
|
|
|
|
|
G. Casaclang-Verzosa, B. J. Gersh, and T. S.M. Tsang Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 1 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel Natriuretic Peptides J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2357 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Lee and T. H. Marwick Assessment of subclinical left ventricular dysfunction in asymptomatic mitral regurgitation Eur J Echocardiogr, June 1, 2007; 8(3): 175 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. P. Griffin Timing of Surgical Intervention in Chronic Mitral Regurgitation: Is Vigilance Enough? Circulation, May 9, 2006; 113(18): 2169 - 2172. [Full Text] [PDF]
|
|
|
|
 |
|
 BNP's Prognostic Value in Mitral Regurgitation Journal Watch Cardiology, July 8, 2005; 2005(708): 4 - 4. [Full Text]
|
|